What is the appropriate management of hypothyroidism, including levothyroxine dosing, titration, and monitoring?

Management of Hypothyroidism

Levothyroxine monotherapy remains the standard of care for hypothyroidism, with dosing individualized by age, cardiac status, and body weight, administered on an empty stomach 30–60 minutes before breakfast, and titrated every 4–8 weeks based on TSH until the target range of 0.45–4.12 mIU/L is achieved. 1, 2, 3

Initial Levothyroxine Dosing

Young Healthy Adults (Age < 50 Years, No Cardiac Disease)

• Start at full replacement dose of 1.6 µg/kg/day calculated on ideal body weight, not actual weight. 1, 2, 4, 3
• This approach achieves rapid TSH normalization and is preferred when residual thyroid function is minimal. 1, 2

Older Adults (Age ≥ 50–60 Years, No Cardiac Disease)

• Begin with 50 µg daily and titrate upward gradually. 1, 2, 4, 3
• Elderly patients require 20–25% less levothyroxine per kilogram due to reduced lean body mass and slower hormone metabolism. 2, 4

Patients with Known or Suspected Coronary Heart Disease (Any Age)

• Initiate at 12.5–25 µg daily to minimize risk of precipitating angina or arrhythmias. 1, 2, 4, 3
• Monitor closely for anginal symptoms with each dose increase. 2, 5, 3
• Titrate every 6–8 weeks (rather than the standard 4–6 weeks) to avoid exacerbating cardiac symptoms. 5, 3

Very Elderly or Frail Patients (Age > 80 Years)

• Start with 20 µg daily and aim for TSH of 1–8 mIU/L, keeping TSH above 1 mIU/L to avoid iatrogenic thyrotoxicosis. 2

Subclinical Hypothyroidism Dosing

TSH > 10 mIU/L

• Treat all patients with levothyroxine regardless of symptoms, as this population has increased risk for heart failure and cardiovascular mortality. 1, 5
• Start with 50 µg daily for TSH 8–12 mIU/L or 75 µg daily for TSH > 12 mIU/L. 1, 5, 4

TSH 4.5–10 mIU/L

• Routine treatment is NOT recommended for asymptomatic patients without high-risk features. 5
• Consider treatment in patients with: symptoms suggestive of hypothyroidism, positive TPO antibodies, atherosclerotic cardiovascular disease, heart failure, or pregnancy/pre-conception planning. 1, 5
• Start with 25 µg daily for TSH 4.0–8.0 mIU/L. 1, 2, 5
• Repeat thyroid function tests every 6–12 months in untreated patients to detect progression. 5

Administration Guidelines

Optimal Timing and Technique

• Administer levothyroxine with water on an empty stomach, 30–60 minutes before breakfast or at bedtime ≥ 4 hours after the last meal. 1, 2, 4, 3
• Approximately 70% of oral levothyroxine is absorbed under optimal conditions. 2, 4
• Taking levothyroxine 60 minutes before breakfast yields superior absorption compared to within 20 minutes of a meal. 1, 2

Drug and Food Interactions

• Separate levothyroxine by ≥ 4 hours from calcium, iron, proton-pump inhibitors, bile-acid sequestrants, and antacids to avoid absorption interference. 2, 4, 3
• Evaluate the need for dose adjustments when regularly administering within one hour of foods that may affect absorption (e.g., soy-based products). 3

Pediatric Administration

• For children who cannot swallow tablets, crush the tablet and suspend in 5–10 mL of water, administering immediately by spoon or dropper. 3
• Do not store the suspension or administer in soybean-based infant formula. 3

Dose Titration and Monitoring

Titration Protocol

• Increase levothyroxine by 12.5–25 µg every 4–8 weeks based on repeat TSH until euthyroidism is achieved. 1, 2, 4, 3
• Smaller dose adjustments (≤12.5 µg) may require ≥ 8 weeks for TSH to plateau before the next change. 2, 4
• The peak therapeutic effect of a given dose may not be attained for 4–6 weeks. 3

TSH Monitoring Schedule

• Check TSH 4–8 weeks after therapy initiation or any dose change. 1, 2, 4, 3
• Once stable replacement is achieved, monitor TSH every 6 months initially, then annually. 1, 2
• More frequent monitoring is needed if compliance is poor or values are abnormal. 3

Therapeutic TSH Targets

• Primary hypothyroidism in adults: target TSH 0.45–4.12 mIU/L (many clinicians prefer the lower half of the reference range). 1, 2
• Elderly patients (60–80 years): target TSH 1–8 mIU/L, maintaining > 1 mIU/L. 2
• Very elderly (> 80 years): use age-adjusted target (approximately age ÷ 10). 2
• Pregnancy: First trimester < 2.5 mIU/L, second trimester < 3.0 mIU/L, third trimester < 3.5 mIU/L. 1, 2, 5

Special Populations

Pregnancy

• Pregnant women or those planning pregnancy should receive levothyroxine for any TSH elevation to protect fetal neurodevelopment. 5
• Increase weekly levothyroxine dosage by 30% (take one extra dose twice per week) upon pregnancy confirmation. 2
• Monitor TSH every 4 weeks during the first half of gestation and at least once between 26–32 weeks. 1, 2, 5
• Measure total T4 in addition to TSH during pregnancy, targeting approximately 1.5-fold higher than non-pregnant reference range. 1, 2

Central (Secondary/Tertiary) Hypothyroidism

• Screen for adrenal insufficiency before starting levothyroxine; administer physiologic hydrocortisone until adrenal insufficiency is excluded to prevent adrenal crisis. 2, 4, 3
• Do not use TSH to guide therapy; monitor free T4 and target the upper half of the normal reference range. 2, 4, 3
• Start at approximately 1.6 µg/kg/day after ensuring adrenal sufficiency. 2, 4

Athyreotic Patients (Post-Thyroidectomy or Radioiodine)

• May require doses higher than the standard 1.6 µg/kg/day. 1, 2, 4

Common Pitfalls and How to Avoid Them

Non-Compliance Masquerading as Treatment Failure

• Persistent TSH elevation despite doses > 200 µg/day most often reflects non-compliance, not malabsorption. 2, 4
• Verify adherence before escalating the dose or pursuing malabsorption workup. 2, 4, 3
• Missed doses should be made up when recognized, even on the same day. 2

Overtreatment Risks

• Approximately 20% of patients on thyroid hormone experience overtreatment. 2
• Overtreatment markedly increases risk of atrial fibrillation in elderly patients, accelerates bone loss in postmenopausal women, and causes mood disturbances. 2, 3
• Avoid targeting subnormal TSH (< 0.45 mIU/L) in non-pregnant adults, as this increases cardiovascular and skeletal risks without proven benefit. 2

Cardiac Safety

• In patients with coronary disease, monitor for anginal symptoms with each dose increase; angina may limit achievement of full euthyroidism. 2, 5, 3
• If cardiac symptoms develop or worsen, reduce the dose or withhold for one week and restart at a lower dose. 3

Adrenal Crisis Prevention

• Always exclude or treat adrenal insufficiency before initiating levothyroxine in patients with central hypothyroidism or suspected hypopituitarism. 2, 4, 3
• Thyroid hormone increases metabolic clearance of glucocorticoids and can precipitate acute adrenal crisis. 3

Factors Requiring Dose Adjustment

Increased Levothyroxine Requirements

• Pregnancy (increase by 30%). 2
• Addition of absorption-interfering medications (calcium, iron, PPIs, bile-acid sequestrants). 2, 4
• Waning residual thyroid function over time. 2

Decreased Levothyroxine Requirements

• Advancing age (20–25% reduction in elderly). 2, 4
• Significant weight loss. 2
• Removal of interfering medications. 2

Contraindicated and Not Recommended Therapies

Desiccated Thyroid Hormone

• Not recommended for hypothyroidism; no evidence shows superiority over levothyroxine monotherapy. 1, 2, 6
• Content of thyroid hormone and T4:T3 ratio may vary by brand and animal source. 1

T3/T4 Combination Therapy

• Should be avoided in pregnant women, women planning pregnancy, and frail elderly patients with cardiac disease. 2
• No consistently strong evidence for superiority over levothyroxine monotherapy in improving health outcomes. 6

Referral to Endocrinology

Refer when:

• Difficulty achieving or maintaining euthyroidism despite appropriate dosing. 2, 4
• Pregnancy or pre-conception planning. 2, 5, 4
• Presence of cardiac disease complicating management. 2, 4
• Goiter, thyroid nodules, or structural thyroid abnormalities. 2, 4
• Coexisting endocrine disorders (adrenal insufficiency, pituitary disease). 2, 4
• Unusual thyroid function test patterns or suspected malabsorption. 2, 4
• Pediatric patients. 2